Our main conclusion of this study is that the majority of patients with symptomatic GATA2 deficiency will need allo-HSCT, and close surveillance of these patients is important to find the “optimal window” for allo-HSCT. This evidence concerns the gene GATA2 and hyperinsulinemic hypoglycemia, familial, 4.